Mesoblast FY Loss Widens; Stock Down

Mesoblast Limited reported a widened net loss of US$102.14 million for the fiscal year ended June 30, 2025, despite cell therapy product revenues surging 191% to US$17.2 million, primarily driven by the successful launch of Ryoncil. While net loss per share narrowed to 8.46 cents, the market reacted negatively to the results, with the stock dropping over 10% in after-hours trading, signaling investor concern over the expanding bottom-line loss despite significant top-line growth.

Analysis

Mesoblast Limited's fiscal year 2025 results present a conflicting picture of strong commercial momentum against deteriorating profitability. The company achieved a significant 191% year-over-year increase in revenue from cell therapy products, reaching US$17.2 million, a success attributed to the final-quarter launch of its Ryoncil product. However, this top-line strength was overshadowed by a widening net loss, which grew to US$102.14 million from US$87.96 million in the prior year. While the net loss per share narrowed slightly to 8.46 cents, the market's response was decisively negative. The stock's 10.97% decline in after-hours trading indicates that investors are prioritizing the increased cash burn and lack of profitability over the initial revenue growth, signaling concerns that operating expenses are outpacing the early commercial ramp-up.

Key Decisions for Investors

• Investors must weigh the high-growth narrative, driven by the 191% revenue surge from the Ryoncil launch, against the fundamental risk of an expanding US$102.14 million net loss.
• Given the sharp post-earnings stock drop of nearly 11%, it is crucial to monitor for signs of stabilization or further downside momentum before initiating or adding to a position.
• Focus should be on future quarters to assess if Ryoncil's sales trajectory can accelerate sufficiently to create operating leverage and reverse the trend of widening losses, as this is the primary concern reflected in the market's negative reaction.